HONGLI GROUP INC
HLPNASDAQTrading Snapshot
- Day Range
- $4.07 – $4.22
- 52-Week Range
- $0.34 – $4.22
- Volume (shares)
- 232,000
- Avg Volume (shares)
- —
- Shares Outstanding
- 74.7M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- $20M
- Last Q Revenue
- $10M
- P/E Ratio
- 158.1
- P/S Ratio
- 16.0x
- EPS (TTM)
- $0.03
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −0.2%
HONGLI GROUP INC
HLP
StockOtter · stockotter.spaceAbout HONGLI GROUP INC
Hongli Group Inc., through its affiliated entities, specializes in the engineering, tailoring, production, and distribution of cold roll-formed steel profiles. These precision components are utilized in a variety of machinery and equipment, with a market reach that extends across the People's Republic of China, South Korea, Japan, the United States, and Sweden. The company's products cater to essential sectors such as mining and excavation, construction, agriculture, and transportation. Established in 2021, the firm's corporate headquarters are situated in Weifang, China. Hongli Group Inc. operates as a subsidiary of Hongli Development Limited.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
Hongli Group Provides Strategic Update on Proposed Advanced Battery Collaboration as Xell Energy Achieves Drone Customer Design Wins
Xell Energy completes product development and customer evaluation of ultra-high-energy-density 420 Wh/kg battery packs WEIFANG, China, Oct. 13, 2026 /PRNewswire/ -- Hongli Group Inc. (the "Company") (Nasdaq: HLP), a cold
Helus Pharma: A Buy Ahead Of The HLP003 Phase 3 Readout
Helus Pharma remains a buy, as HLP003's Phase 3 APPROACH topline data in 4Q26 is the key near-term catalyst. HLP003 targets adjunctive MDD with a differentiated intermittent dosing model; prior Phase 2 data showed a 23-p
Hongli Group Inc. Announces Appointment of Mr. Michael W.
WEIFANG, China, Oct. 5, 2026 /PRNewswire/ -- Hongli Group Inc. (the "Company") (Nasdaq: HLP), a cold roll formed steel profile manufacturer, today announced a leadership transition within its Board of Directors (the "Boa
Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression
Helus Pharma, formerly known as Cybin NASDAQ: HELP, outlined its late-stage development plans for HLP-003 in adjunctive major depressive disorder (MDD) and discussed its broader pipeline of serotonergic agonists during T
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
Poster presentations further characterize clinical profile of HLP003 and Phase 3 PARADIGM program evaluating HLP003 as a potential adjunctive treatment for major depressive disorder (“MDD”) NEW YORK and TORONTO, Sept. 2
Helus Pharma: An Undervalued Psychedelic Platform Approaching A Major Catalyst
Helus Pharma has built a proprietary psychedelic pipeline that currently spans MDD and GAD. The company has two clinical-stage assets and a broader serotonergic discovery platform. Early HLP003 (oral psilocin) and HLP004